Biomarker-first, mri-second pathway
Biomarker-first, mri-second pathway has been studied in 1 paper since 2026: none in people yet, 1 review; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Oct 27, 2026: “The future of prostate cancer screening: from prostate-specific antigen to smart, risk-adapted pathways”.
1 paper studies it1 findingUpdated
1 new paper in 30 daysSee all 1 papers on biomarker-first, mri-second pathway
What did studies of biomarker-first, mri-second pathway find?
1Studies of biomarker-first, mri-second pathway measured one outcome, harms of prostate cancer screening.
Harms of prostate cancer screening
downin humans1
1 study
Harms of prostate cancer screening
downin humans1
Biomarker-first, mri-second pathway decreases harms of prostate cancer screening in humans.
“A biomarker-MRI pathway offers a practical, evidence-supported strategy to meaningfully reduce the harms of prostate cancer screening while preserving detection of clinically significant disease.”
Reviewmales
Current opinion in urology